SOURCES SOUGHT
B -- Support the review and management of the AsiaLymph study-related activities in 7 Taiwanese hospitals
- Notice Date
- 8/26/2013
- Notice Type
- Sources Sought
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- SS-NCI-130136-TG
- Archive Date
- 9/18/2013
- Point of Contact
- Terry Galloway, Phone: 240-276-5384, Seena Ninan, Phone: 240-276-5419
- E-Mail Address
-
gallowaytl@mail.nih.gov, ninans@mail.nih.gov
(gallowaytl@mail.nih.gov, ninans@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Issued By: National Cancer Institute (NCI), Office of Acquisitions (OA) http://www.nci.nih.gov or http://rcb.cancer.gov/rcb-internet/ Key Dates: Capability Statement Due Date: September 3, 2013 by 4:00PM EST This Small Business Sources Sought Notice (SBSS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI). The purpose of this Sources Sought Notice is to identify qualified concerns including 8(a), HUBZone or Service-Disabled Veteran-owned businesses that are interested in and capable of performing the work described herein. The NCI does not intend to award a contract on the basis of responses received nor otherwise pay for the preparation of any information submitted. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This requirement is assigned North American Industry Classification System (NAICS) code 541990 with a size standard of $14.0M is being considered. As a result of this Sources Sought Notice, the NCI may issue a Request for Quotation (RFQ). THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NCI shall arise as a result of a response to this Sources Sought Notice or the NCI's use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement. The contribution of environmental, occupational and genetic factors to lymphoma has generated a series of novel, cutting edge findings in studies of Caucasians. However, the ability to follow-up, confirm and extend these observations has become limited in Western populations, due to the low prevalence and limited range of several important chemical exposures and the high to complete linkage disequilibrium between key candidate genetic loci. Therefore, it is necessary to investigate populations that differ from Caucasians in both exposure patterns and underlying genetic structure. To this end, the National Cancer Institute is conducting a hospital-based case-control study of lymphoma in Eastern Asia (i.e., AsiaLymph). The major postulated risk factors for evaluation in this study are chemical exposures, genetic susceptibility, and infectious agents. A particularly noteworthy aspect of AsiaLymph is central pathology review with immunophenotyping, which will enable accurate analysis of findings by molecular and histologic subtypes. AsiaLymph should confirm and extend previous findings, and yield novel insights into the causes of lymphoma in both Asia and the West. The purpose of this procurement is to support the review and management of the AsiaLymph study-related activities in 7 Taiwanese hospitals (Dalin Tzu Chi General Hospital, China Medical University Hospital, Kaohsiung Chang Gung Memorial Hospital, Chia-Yi Christian Hospital, Kaohsiung Medical University Hospital, National Cheng Kung University Hospital, and Chi-mei Medical Center Hospital) that are enrolling subjects into the AsiaLymph study. To be deemed capable of providing the current need for the services the offeror must submit a written capability statement. The Contractor shall review and manage AsiaLymph-related activities at the 7 Taiwanese hospitals that are enrolling subjects. They will also organize and conduct site-visits with the Taiwan study center and hospitals every 4 months. In addition, the Contractor shall monitor, organize and coordinate shipments of biological samples from Taiwan. The contractor shall conduct the following study tasks: 1. Review and manage AsiaLymph-related activities at the 7 Taiwanese hospitals that are enrolling subjects. Specifically, the contractor shall: a. Host monthly conference calls with the study staff at each participating hospital, to discuss study status and any study-related issues. The list of hospitals and study staff will be provided in the Study Protocol. Issues identified on these calls should be addressed using the materials in the Study Protocol, which will be provided by the NCI within in 15 days of the award. b. In addition to the monthly conference calls, provide support for interviewers and other study staff by responding to questions submitted by email or telephone. Responses to these queries will be developed from the materials in the Study Protocol, which will be provided by the NCI within in 15 days of the award. c. Review study progress in Taiwan and quality controls measures from each hospital bi-weekly. This includes collecting and reviewing: i. Enrollment data ii. Questionnaires iii. Biologic sample specimen information iv. Hospital records 2. Provide monthly summaries of task 1 to the NCI by email or telephone. Urgent issues involving protocol violations must be relayed to the NCI within 24 hours. 3. Organize and conduct site-visits with the Taiwan study center and hospitals every 4 months. The list of hospitals and study center will be provided in the Study Protocol, which will be provided by the NCI within in 15 days of the award. Travel for these site-visits will entail one staff member from the Contractor traveling to the Taiwan Study Center. During these site-visits, training for new staff and re-training in specimen collection and interview administration at each hospital should be conducted, as needed. Spot checks of study-related items, such as collected biological specimens, collected enrollment data, and collected interview data should be conducted to review completeness and correctness as described in the Study Protocol, which will be provided by the NCI within 15 days of the award. 4. Monitor, organize, and coordinate shipments of biological samples from Taiwan. Blood, buccal cell, and pathology specimens will be monitored in an online specimen tracking system, which will be provided by the NCI within 15 days of the award. Buccal and blood samples should be shipped to the NCI by express mail, frozen on dry ice, using tracking. Pathology specimens should be sent to the Pathology Center at the Queen Elizabeth Hospital in Hong Kong. Samples should be shipped overnight, using tracking. Full shipping instructions, including the address, will be contained in the Study Protocol, which will be provided by the NCI within 15 days of the award. This task must be completed for all enrolled cases by the end of the period of performance. 5. Send monthly reports to the NCI on recruitment, diagnosis, and pathology, as described in the Study Protocol, which will be provided by the NCI within 15 days of the award. PERIOD OF PERFORMANCE: The period of performance shall be for 12 months from date of award. How to Submit a Response: 1. Page Limitations: Interested qualified small business organizations should submit a tailored capability statement for this requirement not to exceed 10 single sided pages including all attachments, resumes, charts, etc. (single spaced, 12 point font minimum) that clearly details the ability to perform the requirements of the notice described above. All proprietary information should be marked as such. Responses should include a minimum of a one page resume of the individuals meeting the requirements, and up to two pages demonstrating experience over the past two years meeting the requirements of this notice. Statements should also include an indication of current certified small business status; this indication should be clearly marked on the first page of your capability statement (preferable placed under the eligible small business concern's name and address). Responses will be reviewed only by NIH personnel and will be held in a confidential manner. 2. Due Date: Capability statements are due no later than 11:00 a.m. EST on September 3, 2013. 3. Delivery Point: All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the unique specifications described herein. All questions and responses must be in writing and can be faxed to (240) 276-5401 or emailed to Terry Galloway at gallowaytl@mail.nih.gov. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) through sam.gov. No collect calls will be accepted. Please reference number SS-NCI-130136-TG on all correspondence. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, an RFQ may be issued. However, responses to this notice will not be considered adequate responses to a solicitation(s). Point of Contact: Inquiries concerning this Notice may be direct to: Terry Galloway 9609 Medical Center Dr, Room 1E136 Bethesda, MD 20892-9705 Terry.galloway@nih.gov Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/SS-NCI-130136-TG/listing.html)
- Record
- SN03162468-W 20130828/130826235451-49a890fd6509b835c559a2c87b7f3b49 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |